Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
SBT-101 by SwanBio Therapeutics for Adrenomyeloneuropathy (AMN): Likelihood of Approval
SBT-101 is under clinical development by SwanBio Therapeutics and currently in Phase II for Adrenomyeloneuropathy (AMN). According to GlobalData, Phase...